Search
forLearn
5 / 801 resultslearn nicotinamide
learn Clascoterone
a novel topical treatment that inhibits DHT on androgen receptors
learn Cyproterone
a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor
learn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
Research
5 / 1000+ resultsresearch Novel anti-aging gene NM_026333 contributes to proton-induced aging via NCX1-pathway
The gene NM_026333 slows down aging by affecting the NCX1 pathway and could be targeted for anti-aging treatments.
research Hormonal Control of Cardiac Action Potential Phase 1 Currents in the Brugada Syndrome
Androgens may increase arrhythmias in Brugada Syndrome, while Finasteride could reduce them.
research Emerging Roles for Ion Channels in Ovarian Cancer: Pathomechanisms and Pharmacological Treatment
Ion channels play a key role in ovarian cancer growth and treatment resistance.
research S100A6 Protein—Expression and Function in Norm and Pathology
S100A6 protein is linked to disease progression, especially in cancers.
research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
Community Join
5 / 1000+ resultscommunity Kintor KX -826 Pyrilutamide Adds 1 Year Phase 3 Trial For Safety
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.
community Anageninc no longer sell KX-826 (Pyrilutamide) due to receiving a cease and desist letter from Kintor :(
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.
community REVOLUTION in AUGUST: New possibilities according to Dr. Muñoz (pinacidil, cromakalim, diazoxide and nicorandil)
Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.
community Kintor develop GT20026 Anti-Androgen receptor drug with NO SIDES
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.
community Kintor has released an investor relations memo regarding Chinese Phase III trials for Pyrilutamide
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.